3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
5
Docetaxel
4
tislelizumab
3
Bortezomib
3
spartalizumab
2
pembrolizumab
2
Nivolumab
2
Irinotecan
2
Filgrastim
2
Cisplatin
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
tinostamustine
1
talazoparib
1
surufatinib
1
regorafenib
1
pazopanib
1
pamiparib
1
liposomal doxorubicin
1
isophosphamide mustard
1
futibatinib
1
etoposide phosphate
1
entinostat
1
cc-486
1
cabozantinib
1
atezolizumab
1
anlotinib
1
Vinorelbine
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
futibatinib
×
Sarcoma
×
Clear all
NCT05827614
2026-06-08
POTENTIATE
Boundless Bio, Inc.
Phase 1
Terminated
85 enrolled